Skip to main content

Evidence gap analysis

Strategic analysis of the sufficiency of evidence to obtain reimbursement and HTA approval in Europe and recommendations about evidence generation

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Forty-eight applications for innovation funding for healthcare research projects were accepted in Germany

On May 17, 2024, the Innovation Committee at the Federal Joint Committee (G-BA) announced that forty-eight applications for innovation funding of healthcare research projects were accepted.

The forty-eight applications that were accepted concerned the following topics:

  • Health services research on group settings in the medicinal products sector: 3;
  • Health care research on undesirable consequences of treatment: 6;
  • Patient empowerment: 13;
  • Health care research to improve care for people with hearing loss: 5;
  • Care of patients with post-viral symptom complexes such as post-/long-COVID, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): 8;
  • Open topic: 13.

In total, the Innovation Committee received 236 applications for its two funding announcements (topic-specific and open-topic) of June 30, 2023 (changed on November 16, 2023). 155 of these related to the topic-specific funding announcement, 81 to the open-topic announcement.

The initial overview of the new projects is expected to be published on the Innovation Committee's website in June 2024, once the applicants have accepted the funding conditions and the decisions thus become binding.

The full details in German can be found here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.